Cargando…

Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis

Detalles Bibliográficos
Autores principales:	Zhou, Yu-Jie, Zheng, Kenneth I., Wang, Xiao-Bo, Yan, Hua-Dong, Sun, Qing-Feng, Pan, Ke-Hua, Wang, Ting-Yao, Ma, Hong-Lei, Chen, Yong-Ping, George, Jacob, Zheng, Ming-Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Association for the Study of the Liver. Published by Elsevier B.V. 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195041/ https://www.ncbi.nlm.nih.gov/pubmed/32348790 http://dx.doi.org/10.1016/j.jhep.2020.04.027

Ejemplares similares

Reply to: ‘Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis’
por: Ji, Dong, et al.
Publicado: (2020)

MAFLD: How is it different from NAFLD?
por: Gofton, Cameron, et al.
Publicado: (2023)

From NAFLD to MAFLD: a “redefining” moment for fatty liver disease
por: Zheng, Kenneth I., et al.
Publicado: (2020)

Reply to "Does MAFLD really increase the severity of COVID-19?"
por: Pan, Lu, et al.
Publicado: (2021)

From MAFLD to hepatocellular carcinoma and everything in between
por: Bae, Sarah Da Won, et al.
Publicado: (2022)

MAFLD: an optimal framework for understanding liver cancer phenotypes
por: Crane, Harry, et al.
Publicado: (2023)

Increased Serum Adipsin Correlates with MAFLD and Metabolic Risk Abnormalities
por: Pan, Jie, et al.
Publicado: (2023)

Non-Obese MAFLD Is Associated with Colorectal Adenoma in Health Check Examinees: A Multicenter Retrospective Study
por: Fukunaga, Shuhei, et al.
Publicado: (2021)

Does MAFLD really increase the severity of COVID-19?
por: Fajar, Jonny Karunia, et al.
Publicado: (2021)

Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease
por: Zheng, Kenneth I., et al.
Publicado: (2020)

An international multidisciplinary consensus statement on MAFLD and the risk of CVD
por: Zhou, Xiao-Dong, et al.
Publicado: (2023)

Association and Interaction Between Serum Interleukin-6 Levels and Metabolic Dysfunction-Associated Fatty Liver Disease in Patients With Severe Coronavirus Disease 2019
por: Gao, Feng, et al.
Publicado: (2021)

Comparison of MAFLD and NAFLD Characteristics in Children
por: Xing, Yunfei, et al.
Publicado: (2023)

A prospective multicenter cohort study of frailty in younger critically ill patients
por: Bagshaw, M., et al.
Publicado: (2016)

Role of Insulin Resistance in MAFLD
por: Sakurai, Yoshitaka, et al.
Publicado: (2021)

The Gut Microbiome and Ferroptosis in MAFLD
por: Ji, Jie, et al.
Publicado: (2023)

MAFLD: a multisystem disease
por: Pipitone, Rosaria Maria, et al.
Publicado: (2023)

NAFLD/MAFLD: New Evidence
por: Mantovani, Alessandro, et al.
Publicado: (2023)

Editorial: The NAFLD-MAFLD conundrum
por: Dalbeni, Andrea, et al.
Publicado: (2023)

MAFLD and Celiac Disease in Children
por: Scapaticci, Serena, et al.
Publicado: (2023)

MAFLD enhances clinical practice for liver disease in the Asia-Pacific region
por: Kawaguchi, Takumi, et al.
Publicado: (2022)

Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) and Viral Hepatitis
por: Wang, Xiaolin, et al.
Publicado: (2022)

Erratum to: A prospective multicenter cohort study of frailty in younger critically ill patients
por: Bagshaw, Sean M., et al.
Publicado: (2016)

Increased risk of incident diabetes in patients with MAFLD not meeting the criteria for NAFLD
por: Park, So Hee, et al.
Publicado: (2023)

Impact of MAFLD on the complications after hepatectomy in patients with HBV-related hepatocellular carcinoma
por: Xiong, Ke-Gong, et al.
Publicado: (2023)

Trimethylamine-N-Oxide Pathway: A Potential Target for the Treatment of MAFLD
por: Li, Xun, et al.
Publicado: (2021)

Radiomics based on fluoro-deoxyglucose positron emission tomography predicts liver fibrosis in biopsy-proven MAFLD: a pilot study
por: Chen, Zhong-Wei, et al.
Publicado: (2021)

MAFLD and CKD: An Updated Narrative Review
por: Mantovani, Alessandro, et al.
Publicado: (2022)

Emerging pharmacological treatment options for MAFLD
por: Rojas, Ángela, et al.
Publicado: (2022)

Screening for MAFLD: who, when and how?
por: Pal, Shreya C., et al.
Publicado: (2023)

Prediction of MAFLD and NAFLD using different screening indexes: A cross-sectional study in U.S. adults
por: Peng, Hongye, et al.
Publicado: (2023)

Attenuating effect of Polygala tenuifolia Willd. seed oil on progression of MAFLD
por: Xin, Meiling, et al.
Publicado: (2023)

Advancements in MAFLD Modeling with Human Cell and Organoid Models
por: Wang, Shi-Xiang, et al.
Publicado: (2022)

Correlation between serum uric acid and body fat distribution in patients with MAFLD
por: Tao, Min, et al.
Publicado: (2023)

Editorial: The Metabolic (Dysfunction) Associated Fatty Liver Disease (MAFLD)-Non-Alcoholic Fatty Liver Disease (NAFLD) Debate: A Forced Consensus and The Risk of a World Divide
por: Méndez-Sánchez, Nahum, et al.
Publicado: (2022)

Lead exposure as a causative factor for metabolic associated fatty liver disease (MAFLD) and a lead exposure related nomogram for MAFLD prevalence
por: Yang, Chenyu, et al.
Publicado: (2022)

MAFLD in Obese Children: A Challenging Definition
por: Di Sessa, Anna, et al.
Publicado: (2021)

COVID-19 and MAFLD/NAFLD: An updated review
por: Nowroozi, Ali, et al.
Publicado: (2023)

Contribution of classification based on ferroptosis-related genes to the heterogeneity of MAFLD
por: Dai, Xin, et al.
Publicado: (2022)

Cardiovascular and renal burdens among patients with MAFLD and NAFLD in China
por: Wang, Yuying, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pslnsli5ss9hvld1ipuluv30rm